Maricann Group Inc. (CSE:MARI; FWB:75M; OTCQB:MRRCF)is excited to announce the official launch of MariPlant, the Company’s European nutraceutical line of business. MariPlant products will be available for sale in Germany through www.mariplant.de beginning on August 20, 2018, with strategic expansion planned throughout the European Union.  Maricann’s first product launch is a soft gel formulation loaded with 25mg of CBD that utilizes the multi-patented VESIsorb® delivery system to ensure optimum absorption and bioavailability.

“Maricann is pleased to bring a superior CBD product to the German marketplace. This development symbolizes a significant move to strengthen our global leadership position as we introduce the first of many patented formulations that utilize VESIsorb,” Stated Ben Ward, CEO.


Maricann’s product launch represents many first-to-market milestones in the German cannabis industry, including the first:

  • VESIsorb® formulation specifically adapted for cannabinoids;
  • Standardized CBD product with measured and proven stability data; and
  • Formulation with a strategic CBD:BCP (beta-caryophyllene) ratio of 4:1

In 2017, through a commercialization agreement with SourceOne Global Partners, Maricann acquired the supply rights to VESIsorb® for use with cannabis for human consumption in Canada, Germany, and other territories.

Multiple clinical studies have demonstrated the absorption and bioavailability benefits of VESIsorb®, a science-backed drug delivery technology with a robust portfolio of international patents. VESIsorb® has now been successfully adapted to optimize the performance of cannabis formulations in the human body. Since 2007, close to 200 million consumers in all six continents have safely and effectively used a natural product formulated with VESIsorb®.

According to Jesse Lopez, CEO and founder of SourceOne Global Partners, Maricann’s commitment to building an immediate infrastructure for German market leadership has pioneered a new standard for cannabis products in Europe. “Maricann has all of the critical elements to champion the VESIsorb® drug delivery system in the emerging global cannabis industry. With a focus on innovation and clinical research, they also have the financial strength to build awareness and educate consumers on these superior product applications,” Lopez said.

About Maricann Group Inc.

Maricann is a vertically integrated producer and distributor of cannabis for medical purposes. The company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the Government of Canada. The Company also has production operations in Dresden, Saxony, Germany and Regensdorf, Switzerland. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000 sq. ft. (87,515 sq. m) facility and will continue to pursue new opportunities in Europe.

Forward Looking Statements

This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Click here to connect with Maricann Group Inc. (CSE:MARI; FWB:75M; OTCQB:MRRCF) for an Investor Presentation

An Emerging Markets Sponsored Commentary

A report just released in early April confirms that the cannabis beverage sector is thriving. According to this report from industry stalwart, Marijuana Business Daily while sales for vapes, pre-rolls and flower were lackluster, cannabis beverages shined:

Keep reading... Show less

BevCanna Enterprises (CSE:BEV,OTCQQ:BVNNF,FWB:7BC) CEO Marcello Leone shared how the company is scaling up its products to forge partnerships and explore opportunities across Canada, the US and Western Europe. 

“Getting your standard processing license and being fully compliant at a federal level is critical in Canada, and we were successful in getting that done. Now we’re getting ready to launch our Keef line of beverages within the next 45 days,” Leone said. 

As a young company, Leone said BevCanna has only started, but it took a four-pronged approach to make sure that it is a revenue-generating company prepared for the opening of many jurisdictions for CBD-based products.

“We are blessed that we have a beautiful infrastructure of our own, a state-of-the-art bottling facility with a capacity of almost 200 million bottles per annum and a strong balance sheet of $55 million. We are in a strong position to scale and grow this company.”

BevCanna has received a Standard Processing License from Health Canada and is now fully authorized to begin production at its full-service, high-capacity beverage manufacturing facility. The company will begin production of its white-label products, number one US cannabis beverage brand Keef and its in-house beverages through licensed Canadian retailers, positioning the company to fully capitalize on the burgeoning Canadian cannabis-infused beverage sector.

Watch the full interview with CEO Marcello Leone above.

Keep reading... Show less

BioHarvest Sciences (CSE: BHSC) will be presenting at the Benzinga Cleantech Small Cap Conference taking place on April 22, 2021. We invite our shareholders and all interested parties to explore cleantech small cap investment opportunities through two days of networking, dealmaking and discovery.

Sign up to get a free spectator pass for the event: https://www.benzinga.com/events/small-cap/clean-tech/

Keep reading... Show less

Positive distributor feedback and strong consumer interest accelerating launch with distributors

Emerging leader in innovative health and wellness beverages and products, BevCanna Enterprises Inc. ( CSE:BEV , Q:BVNNF , FSE:7BC ) (“ BevCanna ” or the “ Company ”) announces today that its wholly-owned subsidiary Naturo Group has successfully completed its initial shipment of TRACE plant-based products to one of Japan’s largest beverage distributors.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or the “Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, today announced an additional refreshment of its board of directors to further strengthen its leadership in the cannabis industry.

Keep reading... Show less